- Case study
- Open Access
Case study to assess the safety of irreversible electroporation near the heart
© Sugimoto et al.; licensee Springer. 2015
- Received: 25 September 2014
- Accepted: 16 January 2015
- Published: 11 February 2015
Irreversible electroporation (IRE) is a promising technique for the focal treatment of soft tissue tumors. Even though the local application of an excessive electric field is a potential cause of cardiac arrhythmias, initial clinical studies have shown that IRE is generally safe when cardiac gating is employed.
In this case report, we observed an episode of ventricular extrasystoles without hemodynamic changes during which time the synchronization device failed to operate properly, with pulses delivered not in the absolute refractory period but in the relative refractory period.
Discussion and evaluation
At present, persons performing IRE must keep in mind that there is a small but real risk of synchronization failure even when a cardiac synchronization device is used.
It is advisable to err on the side of caution when treating lesions near the heart.
- Irreversible electroporation
Irreversible electroporation (IRE) is a new non-thermal local ablative treatment procedure in which irreversible permeabilization of the cell membrane lipid bilayer is induced by the creation of nanopores, resulting in cell death (Davalos et al. 2005). IRE may offer two major potential advantages over commonly employed radiofrequency (RF) thermal ablation approaches for the treatment of hepatic lesions.
The first advantage is that, unlike RF ablation, IRE relies on electrical energy rather than thermal energy to induce cell death, and it appears to be unaffected by nearby vessels (Rubinsky et al. 2007). This suggests that IRE may be more effective for the treatment of areas where tumor cells are in close proximity to large vessels (i.e., no “heat-sink effect”). The second advantage is that IRE may improve safety in the vicinity of heat-sensitive structures such as blood vessels, nerves, bile ducts, and the gastrointestinal tract (Cannon et al. 2013; Schoellnast et al. 2013a; Choi et al. 2014; Schoellnast et al. 2013b). Given its distinctive characteristics, IRE has the potential to become an alternative method for the ablation of solid tumors.
However, specific precautions are required because the delivery of powerful electrical pulses to human tissue has the potential to cause fatal cardiac arrhythmias (Ball et al. 2010). Cardiac screening and synchronized pulsing are therefore absolutely imperative (Deodhar et al. 2011). In an initial clinical study in which cardiac synchronization was employed, only atrial arrhythmias occurred in 4 cases, and these resolved spontaneously or within 24 hours after therapy (Scheffer et al. 2014). Accordingly, initial clinical studies have concluded that IRE may be safe when such measures are taken (Scheffer et al. 2014).
Nonetheless, specific guidelines for the use of IRE (i.e., how close to the heart IRE can safely be performed even with the use of cardiac synchronization) have not yet been established. In this case report, we describe the IRE treatment of metastatic liver lesions located in close proximity to the inferior border of the heart.
A 48-year-old man who had recently undergone resection of a moderately differentiated invasive adenocarcinoma of the rectum presented with focal liver lesions measuring 15 mm, 16 mm, and 9 mm in segments 8, 4, and 2 of the liver, respectively, which were newly diagnosed by MR imaging. No other metastatic lesions were detected by PET. He had not a prior medical history of other conditions, including heart disease. He had received one cycle of modified FOLFOX6 chemotherapy (l-leucovorin, 5-fluorouracil, and oxaliplatin), but this treatment was halted due to adverse events such as pancytopenia and malaise. He was therefore referred to our department. After discussing treatment options, including resection and ablation, the decision was made to proceed with IRE for these metastases as a part of a clinical trial (UMIN000014522).
We performed ultrasound (US)-guided IRE (NanoKnife; AngioDynamics, Latham, NY, USA) with the patient under general anesthesia with neuromuscular blockade to avoid muscle contraction. All interventions were performed percutaneously using a dedicated US system (Aplio™ 500; Toshiba, Tochigi, Japan) equipped with a 3.75-MHz convex transducer (PVT-385BT; Toshiba, Tochigi, Japan). In addition, to prevent pulse-induced arrhythmias, a preprogrammed commercial ECG trigger monitor (AccuSync 72; AccuSync Medical Research Corporation, Milford, CT, USA) was connected to a five-lead ECG to synchronize pulse delivery within the refractory period of the heart. An external biphasic defibrillator was also prepared and was immediately available for the treatment of ventricular arrhythmias.
Considering the size and shape of each lesion and including a 1-cm tumor-free margin, we determined the number and configuration of electrodes. The voltage was also determined using a standard algorithm (AngioDynamics) based on factors such as the intended size of the ablation zone, the number of probes, the distance between the probes, and the length of the active electrode tip (Thomson et al. 2011). Accordingly, three insulated 15-cm needle electrodes with an exposure length of 20 mm were placed in the outer border of the tumor under US guidance. All needles were placed as parallel to one another as possible to help ensure homogeneous energy delivery.
In a previous animal study, which was conducted using a 2-electrode configuration, all cells within a radius of 1.7 cm from each applicator were found to show a transient or permanent increase in cell membrane permeability, suggesting that the delivery of IRE pulses within 1.7 cm of the myocardium could induce arrhythmias (Deodhar et al. 2011). Accordingly, the authors of that study stated that when performing IRE ablation, in order to avoid inducing ventricular arrhythmias, the distance from the heart should be greater than 1.7 cm or IRE should be performed in synchronized mode (Deodhar et al. 2011).
The findings of initial clinical studies have also shown that IRE is generally safe when cardiac gating is employed: only minor arrhythmias occurred, with a total incidence of 2% (4 of 194) (Scheffer et al. 2014). However, in our case, we are unable to assert the safety of this method because a number of transient ventricular extrasystoles occurred during IRE. In addition, we found that these ventricular extrasystoles occurred when the synchronization device failed to operate properly (i.e., unsuccessful synchronization with the R wave). As a result, some pulses were delivered during the vulnerable period of the ventricular myocardium, which corresponds to almost the entire T wave as seen on the ECG.
Thomson et al. 2011 reported that their team used a preprogrammed commercial ECG trigger monitor (AccuSync 42; AccuSync Medical Research Corporation) and found it to be unsatisfactory because it lost synchronization during IRE, causing the IRE sequence to be aborted. A more advanced synchronization unit (AccuSync 72; AccuSync Medical Research Corporation) was subsequently used successfully.
Nevertheless, we have occasionally encountered such synchronization failure (Figure. 2B) even though the AccuSync 72 was used. Given this situation, one possible solution is to change the lead pair in each case if synchronization failure is observed. However, this phenomenon is considered to be of critical importance because it could induce ventricular arrhythmias if the distance from the heart to the IRE electrode is less than 1.7 cm. We feel that the manufacturer should make further improvements to the device.
Moreover, it is important to emphasize that a 2-electrode configuration was used in the cited study (Deodhar et al. 2011), whereas a 3-electrode configuration was used in the present study. The distance (i.e., distance of the electrodes from the heart) could be affected by the electrode configuration, the geometry, and the electrical properties of the tissues. It is therefore uncertain whether the distance obtained in this study (i.e., 1.7 cm) is a true threshold value or not. Although a fatal adverse event was fortunately avoided in this case, we feel that it would be wise to avoid IRE treatment if the heart lies in the reversibly permeabilized area until improvements are made to the synchronization device to avoid the possibility of synchronization failure.
In conclusion, persons performing IRE must recognize that there is a possibility of synchronization failure. Even when cardiac synchronization is employed, it is better to err on the side of caution when treating lesions located near the heart.
Written informed consent was obtained from the patient for publication of this report and any accompanying images.
- Ball C, Thomson KR, Kavnoudias H (2010) Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 110:1305–1309View ArticleGoogle Scholar
- Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd (2013) Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107:544–549View ArticleGoogle Scholar
- Choi JW, Lu DS, Osuagwu F, Raman S, Lassman C (2014) Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model. Cardiovasc Intervent Radiol 37:224–230View ArticleGoogle Scholar
- Davalos RV, Mir IL, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231View ArticleGoogle Scholar
- Deodhar A, Dickfeld T, Single GW, Hamilton WC Jr, Thornton RH, Sofocleous CT, Maybody M, Gónen M, Rubinsky B, Solomon SB (2011) Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol 196:W330–W335View ArticleGoogle Scholar
- Rubinsky B, Onik G, Mikus P (2007) Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 6:37–48View ArticleGoogle Scholar
- Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, Meijer S, van Kuijk C, van den Tol PM, Meijerink MR (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25:997–1011View ArticleGoogle Scholar
- Schoellnast H, Monette S, Ezell PC, Maybody M, Erinjeri JP, Stubblefield MD, Single G, Solomon SB (2013a) The delayed effects of irreversible electroporation ablation on nerves. Eur Radiol 23:375–380View ArticleGoogle Scholar
- Schoellnast H, Monette S, Ezell PC, Single G, Maybody M, Weiser MR, Fong Y, Solomon SB (2013b) Irreversible electroporation adjacent to the rectum: evaluation of pathological effects in a pig model. Cardiovasc Intervent Radiol 36:213–220View ArticleGoogle Scholar
- Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22:611–621View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.